Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 26, 2007 Ryan Fuhrmann	LabCorp Leaps Forward LabCorp continues to fire on all cylinders. Investors, take note.
The Motley Fool October 24, 2006 Ryan Fuhrmann	LabCorp's Positive Results The good times continue. After taking a major client from Quest Diagnostics, the company reports strong third-quarter earnings.
The Motley Fool July 24, 2006 Ryan Fuhrmann	The Quest for Market Share Quest Diagnostics' second-quarter earnings mostly meet expectations. What might the future hold for investors?
The Motley Fool July 21, 2005 W.D. Crotty	The Lab Is Fab Laboratory Corporation of America produces more healthy results. Quest is a better value today based on earnings growth, but both companies are an excellent bet.
The Motley Fool April 20, 2007 Ryan Fuhrmann	Diagnosing Quest Diagnostics Quest should recover from a recent, painful contract loss. Shares trade for a reasonable 17.5 times earnings, and even lower multiple of free cash flow.
The Motley Fool October 5, 2006 Rich Smith	Great Chemistry at Lab Corp UnitedHealth Group has canceled its lab-testing contract with Quest and named Lab Corp. as its new service provider. This is an interesting situation for investors.
The Motley Fool April 20, 2005 Rich Smith	LabCorp Hides Good News The company inexplicably hides its successful numbers from all but the most resourceful investors.
The Motley Fool February 15, 2007 Ryan Fuhrmann	LabCorp Takes Names Things are going well at LabCorp, but not so well at Quest Diagnostics. Still, the long-term attractiveness of the lab testing industry is favorable as the industry consolidates and demographics support increasing healthcare services.
The Motley Fool February 4, 2011 Brian Orelli	Glaxo Sold Quest Shares. Should You? Glaxo has somewhere else to spend the capital. Do you?
The Motley Fool July 25, 2007 Ryan Fuhrmann	The Latest Procedure From Quest Diagnostics Quest Diagnostics took a hit earlier this year from the loss of a major contract, but the lab testing firm isn't down for the count.
The Motley Fool October 20, 2005 Rich Smith	LabCorp: Boring Can Be Good The company is firmly on track toward this year's goal of $440 million to $465 million in free cash flow. Should the company hit even the low end of that guidance, it would be valued at under 16 times FCF, smack dab in between its projected growth rate and its return on equity.
The Motley Fool February 8, 2007 Rich Duprey	Foolish Forecast: LabCorp Tests Positive The clinical lab-testing outfit is set to report its fourth-quarter 2006 earnings. Investors, here is what you can expect to see.
The Motley Fool March 9, 2007 Ryan Fuhrmann	Referencing Bio-Reference's Q1: Fool by Numbers The Northeastern clinical lab test provider released first-quarter 2007 results. Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool December 9, 2011 Paul Chi	3 Europe-Proof Stocks for Your Portfolio These health-care stocks are Europe-proof.
The Motley Fool September 10, 2010 Anand Chokkavelu	How Expensive Is Abbott Laboratories Stock Right Now? Abbott Laboratories has a mixed performance in hitting the ideal targets, but let's see how it compares against some competitors and industry mates.
The Motley Fool April 19, 2007 Ryan Fuhrmann	Quest Diagnostics Becomes Un-United: Fool by Numbers The lab-testing firm released first-quarter 2007 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool September 7, 2005 Stephen D. Simpson	The Little Lab That Could Bio-Reference is a small business with big potential. The company has an appealing cancer and genomics business (GenPath). For investors seeking successful yet unknown companies, this one is worth watching.
The Motley Fool April 26, 2007 Ryan Fuhrmann	LabCorp Measures Up: Fool by Numbers The lab testing firm released results for the first quarter 2007: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool June 6, 2007 Ryan Fuhrmann	Foolish Forecast: Bio-Reference Labs Nudges Competitors The clinical laboratory testing company is set to release it second-quarter earnings report. Investors, here is what you can expect to see.
The Motley Fool February 13, 2009 Brian Orelli	Lynch Would Love This Company Double-digit revenue growth in this market is nothing to sneeze at, but that's what LabCorp has delivered.
The Motley Fool September 6, 2007 Ryan Fuhrmann	Bio-Reference Labs Passes the Test Small-cap lab-testing firm Bio-Reference Labs third-quarter results beat analysts projections by a decent margin, again proving it can compete with the big boys in the highly competitive New York metro area.
The Motley Fool August 17, 2005 W.D. Crotty	HP's Stuck in the Margins Hewlett-Packard's third quarter shows an improvement in operating margins, but there's still room to improve. The stock is leading the New York Stock Exchange's most actives list and is one of the top five percentage gainers for the day.
The Motley Fool December 16, 2010 Seth Jayson	Why the Street Should Love LabCorp's Earnings With questionable cash flows amounting to only 7.4% of operating cash flow, LabCorp's cash flows look clean.
The Motley Fool April 8, 2008 Colleen Paulson	Invest Where the Jobs Are Think about these growing sectors for your next investing opportunities.
The Motley Fool April 11, 2007 Richard Gibbons	The Market's Most Dangerous Bargains Buying the cheapest-looking stocks can be a really bad idea. Relative valuation can be an indicator of value, but it should go hand-in-hand with other valuation techniques and solid understanding of the fundamentals of the business.
The Motley Fool November 17, 2004 W.D. Crotty	Hurting on the Margin Although operating margins at Hewlett-Packard are improving, they still are below peer levels. At today's stock price, the company offers investors marginal value.
The Motley Fool February 16, 2006 Stephen D. Simpson	Lab Corp Doesn't Pass the Test Lab Corp may be a well-run company, but there just isn't enough room in the stock price.
Managed Care April 2007 Scott Kober	Managed Care Seeks More from Clinical Laboratories Contracting advantage has sometimes been with the nationwide labs, but health plans are getting serious about price, service, and patient data.
The Motley Fool June 15, 2005 Bobby Shethia	A New Test for Quest The medical testing leader hopes to improve its steady performance via the rapidly growing gene-testing market. But sustained growth will require hefty capital expenditures. Investors, take note.
The Motley Fool October 17, 2005 Stephen D. Simpson	Is SuperValu Either? Too many excuses prevent this grocer from being a bargain. A P/E of about 14 exceeds not only the company's growth rate over the past decade but also analyst expectations for the future.
The Motley Fool June 2, 2005 Matt Thurmond	Quality Systems or Not? Quality Systems' growth prospects were trading at a discount back in 2003. Those days are gone. But does that mean you shouldn't buy?
The Motley Fool August 18, 2011 Matt Koppenheffer	3 Companies to Worry About, 3 That Are Safe Just because a company is very profitable right now doesn't mean that it will maintain that same profitability in the years ahead. Take a look at these examples.
The Motley Fool July 8, 2010 Selena Maranjian	Get 2-for-1 Stock-Price Growth This one-two punch can lead to serious gains. Stocks that offer both earnings growth and P/E growth can help you rack up knockout returns over the long haul.
The Motley Fool February 11, 2004 W.D. Crotty	Health-Care Opportunity Health Net looks like a value-priced managed care company.
The Motley Fool May 4, 2005 Rich Smith	Renovating Hooper Holmes This medical services company could be starting a turnaround. This is one for investors to watch.
The Motley Fool September 14, 2011 Frank Vinluan	Here's How New Roche Cancer Drug Zelboraf Benefits LabCorp A new Roche cancer drug expected to become a blockbuster could also end up being a boon for laboratory and diagnostics firm LabCorp.
The Motley Fool July 12, 2006 Tim Beyers	Meet the P/E Ratio You're about to get to know the most maligned metric in investing, the P/E. Why all the hate? Investors, read on.
The Motley Fool March 12, 2007 Ryan Fuhrmann	Esoteric Results at Bio-Reference Labs Bio-Reference Labs is a small firm in the lab-testing field, but worth a look from investors.
The Motley Fool June 7, 2007 Ryan Fuhrmann	Big Gains for a Little Lab-Tester While bigger competitors stumble over each other, Bio-Reference keeps growing. This company may just be a welcome investment alternative as its two larger peers keep getting in each other's way.
Chemistry World November 12, 2014 Phillip Broadwith	Labcorp to buy Covance and enter contract research Medical diagnostics specialist Labcorp has agreed to buy contract research organization Covance for around $6 billion.
The Motley Fool August 19, 2005 Philip Durell	How to Use the P/E The price-to-earnings ratio is a widely used -- and misused -- investing metric. Do you use it correctly?
The Motley Fool April 27, 2007 Ryan Fuhrmann	LabCorp Tests Positive LabCorp is doing well focusing on managed care -- so far. Recent results were "outstanding by every measure" and could signal even better things to come. Investors, take note.
The Motley Fool July 14, 2005 Stephen D. Simpson	A Health-Care Sequoia Growth will slow someday for United Health, but that day hasn't come just yet. Investors, take note.
The Motley Fool May 27, 2005 Matt Thurmond	Attention, Value Shoppers.... When selecting an investment, a low P/E doesn't tell the whole story. Before jumping to conclusions based on a single-digit P/E, step back and try to understand both the company you're considering and the historic and current changes in its industry.
The Motley Fool April 27, 2005 Tim Hanson	Quest for Value and Growth Quest Diagnostics, a consistent winner, could be good medicine for your portfolio.
The Motley Fool October 25, 2010 Rich Smith	This Just In: Upgrades and Downgrades Standpoint Capital believes that ExxonMobil, Quest Diagnostics, and Lockheed Martin have nowhere to go but up.
The Motley Fool January 26, 2007 Jack Uldrich	Big Blue Will See You Now A new medical-records search engine could streamline medical services and improve patient health. This system is just one more reason IBM makes a great blue chip investment.
The Motley Fool June 9, 2005 Richard Gibbons	Buying on Margins Profit margins are one useful tool for finding great stock values.
The Motley Fool October 3, 2007 Jack Uldrich	IBM Will Now See Your Avatar IBM is creating a 3-D representation of patients in the form of an avatar, on which all their digital health-care information can be quickly and easily displayed and, thus, accessed by a doctor. Investors, take note.
The Motley Fool February 15, 2007 Ryan Fuhrmann	Clean Bill of Health at LabCorp: Fool by Numbers The laboratory testing firm released fourth-quarter and year-end 2006 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...